Agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. We are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. 

 Our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. Our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. Our approaches are driven by three platform technologies, including: • Our antibody platforms, including our proprietary Retrocyte Display™ and SECANT® technologies, and our antibody programs, including checkpoint modulators, or CPMs; • Our heat shock protein (HSP)-based vaccines; and • Our saponin-based vaccine adjuvants, principally our QS-21 Stimulon® adjuvant. We are passionate about the work we do every day at Agenus to deliver on the promise of immuno-oncology. If you’re looking for an inspired environment, passionate colleagues, and a culture that nurtures learning, innovation and team success, we invite you to join us. Pipeline 

 From advanced programs in late-stage development to our earlier pre-clinical candidates, Agenus and its partners continue to advance our groundbreaking technologies and product candidates closer to clinical practice and closer to delivering on our promise of treating cancers and infectious diseases.
Company Growth (employees)
Lexington, US
Size (employees)
230 (est)
Agenus was founded in 1994 and is headquartered in Lexington, US

Agenus Office Locations

Agenus has an office in Lexington
Lexington, US (HQ)
3 Forbes Rd

Agenus Data and Metrics

Agenus Financial Metrics

Agenus's revenue was reported to be $22.6 m in 2016 which is a 9% decrease from the previous period.
Numbers are in $, USD

Revenue (Y, 2016)

22.6 m

Revenue growth (Y, 2015 - Y, 2016), %


Net income (Y, 2016)

(127 m)

EBIT (Y, 2016)

(107.5 m)

Market capitalization (26-May-2017)

342 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

71.4 m
Agenus's current market capitalization is $342 m.
Numbers are in $, USDFY, 2013FY, 2014Y, 2015Y, 2016


3 m7 m24.8 m22.6 m

Revenue growth, %


Gross profit

2.5 m

Gross profit Margin, %



(25 m)(43.3 m)(80.7 m)(107.5 m)

EBIT margin, %


Net Income

(30.1 m)(42.5 m)(87.9 m)(127 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


27.4 m25.7 m136.7 m71.4 m

Accounts Receivable

1.2 k9.8 m11.4 m


95.7 k88.2 k88.2 k

Current Assets

28.2 m42.7 m184.1 m91.3 m


2.6 m17.9 m22.8 m22.4 m

Total Assets

34.8 m74.5 m242.2 m157 m

Accounts Payable

834.7 k1.7 m4.5 m5.4 m

Current Liabilities

10.3 m9.2 m28.9 m40.9 m

Additional Paid-in Capital

644.6 m715.7 m851.1 m866.9 m

Retained Earnings

(649.1 m)(691.3 m)(779.2 m)(905.3 m)

Total Equity

70.7 m

Financial Leverage

3.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(30.1 m)(42.5 m)(87.9 m)(127 m)

Depreciation and Amortization

586.3 k1.6 m2 m4.9 m

Accounts Receivable

551.1 k1.2 k(9.3 m)(1.5 m)


16 k(95.7 k)7.5 k7.5 k

Accounts Payable

189.6 k(45.9 k)2.7 m419.7 k

Cash From Operating Activities

(19.5 m)(38.2 m)(47.2 m)(80 m)

Cash From Investing Activities

(363.5 k)(16.8 m)(31.2 m)17.6 m

Long-term Borrowings

(555.6 k)(3.3 m)

Dividends Paid

(461 k)(461 k)

Cash From Financing Activities

25.8 m52.8 m189.6 m(2.5 m)

Interest Paid

579.7 k675.4 k1.1 m1.1 m
Numbers are in $, USDY, 2016


98.1 k

Agenus Market Value History

Agenus Median Salaries

Source: 15 public H-1B filings from Agenus

Agenus Online and Social Media Presence

Agenus Company Life and Culture

You may also be interested in